KRAS and pachyonychia congenita: Even though multigene NGS is not currently recommended in patients with advanced PC in clinical practice, experts proposed its application in the context of molecular screening programs by clinical research centers as a tool to screen patients eligible for clinical trials, to accelerate drug development, and to increase the sensitivity, negative predictive value, and accuracy of cytopathology in the diagnosis of PC and differential diagnosis with chronic pancreatitis through the potential combination of the KRAS mutation assay with endoscopic ultrasonography-guided cytopathology [78].